Cancer screenings are key to saving lives. Take colonoscopies, for example, which are estimated to reduce colorectal cancer risk by about 30%. This is because undergoing colonoscopies as recommended (every 10 years beginning at...
Exercise associated with increased survival after colon cancer, and screening costs remain a hurdle for women with dense breasts.
Men with metastatic prostate cancer urged to ask questions about care, and early-phase study suggests benefit of pancreatic cancer vaccine.
This month, the editors of AACR's journals show their love for studies about CAR T-cell efficacy, breast cancer risk, and more.
Radiation plus immunotherapy may help some patients with invasive bladder cancer keep their bladders. Patients with localized muscle-invasive bladder cancer (MIBC), or bladder cancer that has spread through the lining of the bladder and...
The FDA has approved a CSF1 small molecule inhibitor for certain patients with symptomatic tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza) for the treatment of adult...
Pesticide firms try to block cancer-related lawsuits, and cancer pain leads to greater tobacco and cannabis use.
Researchers are examining ways to make treatments more targeted to each type of biliary tract cancer or to each patient.
The FDA has approved the antibody-drug conjugate brentuximab vedotin, plus lenalidomide and rituximab, for certain cases of pretreated large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris), in...
The FDA has approved a new MEK inhibitor for certain patients with symptomatic neurofibromatosis type 1. The U.S. Food and Drug Administration (FDA) has approved mirdametinib (Gomekli) for the treatment of patients with neurofibromatosis...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now